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ABSTRACT: Introduction. Brain perfusion studies with single-photon emission computed tomog-
raphy (SPECT) have been applied in demented patients to provide better discrimination between
frontotemporal dementia (FTD) and Alzheimer’s disease (AD).
Aim. To assess the perfusion of specific Brodmann (Br) areas of the brain cortex in FTD and
AD patients, using NeuroGam processing program to provide 3D voxel-by-voxel cerebral SPECT
analysis.
Material and methods. We studied 34 consecutive patients. We used the established cri-
teria for the diagnosis of dementia and the specific established criteria for the diagnosis of FTD
and AD. All the patients had a neuropsychological evaluation with a battery of tests including
the mini-mental state examination (MMSE).Twenty-six patients (16 males, 10 females, mean age
68.76±6.51 years, education 11.81±4.25 years, MMSE 16.69±9.89) received the diagnosis of
FTD and 8 patients (all females, mean age 71.25±10.48 years, education 10±4.6 years, MMSE
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12.5±3.89) the diagnosis of AD. All the patients underwent a brain SPECT. We applied the Neu-
roGam Software for the evaluation of brain perfusion in specific Br areas in the left (L) and right
(R) hemispheres.
Results. Statistically significant hypoperfusion in FTD compared to AD patients, was found
in the following Br areas: 11L (p<0.0001), 11R, 20L, 20R, 32L, 38L, 38R, 44L (p<0.001), 32R,
36L, 36R, 45L, 45R, 47R (p<0.01), 9L, 21L, 39R, 44R, 46R, 47L (p<0.05). On the contrary, AD
patients presented significant (p<0.05) hypoperfusion in 7R and 39R Br areas.
Conclusion. NeuroGam processing program of brain perfusion SPECT could result in en-
hanced accuracy for the differential diagnosis between AD and FTD patients.
KEYWORDS: Gamma camera, SPECT, PET PET/CT, coronary CT angiography (CTA); Medical-
image reconstruction methods and algorithms, computer-aided so
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Frontotemporal dementia (FTD) and Alzheimer’s disease (AD) have been recognized as distinct
clinical syndromes for a number of years, the former considered to be one of the most common
neurodegenerative dementia syndromes after AD and dementia with Lewy bodies [1].
AD was first described by Alois Alzheimer and has been shown by many investigators to be
the most prevalent form of dementia in the elderly throughout the world [2]. The clinical course
of AD can be divided into three stages with memory difficulties to be among the first and the
most striking cognitive manifestations of the disease. As the disease progress into the second
stage, agnosia, aphasia and apraxia may appear, while in the third stage weight loss and motor
impairment may be added and death occurs inevitably [3]. The basic pathological feature of AD
consists of whole brain atrophy, cortical cell loss, neurofibrillary degenerative changes in neurons
and neuritic plaques of amyloid accumulation across the cortex [2].
FTD is the preferred term used to describe a spectrum of non-Alzheimer’s degenerative condi-
tions associated with focal atrophy of the frontal and/or the temporal lobes [4]. The clinical course
of FTD can also be divided into three stages and begins with significant personality and behav-
ioral alterations, lack of awareness, and poor judgment [5]. The second stage is characterized by
increasing cognitive problems with language deficits being the most prominent and finally, in the
third stage, patients often become aphasic and progress to complete muteness.
There have been proposed some specific clinical criteria for the diagnosis of AD and FTD.
For the diagnosis of AD, there are at least two sets of clinical criteria, the first one is described
in the Diagnostic and Statistical Manual-IV (DSM-IV) and the second one was developed by the
National Institute of Neurologic and Communicative Disorders and Stroke and the AD and Related
Disorders Association Work Group (NINCDS-ADRDA) [1]. The corresponding criteria for FTD
are the Lund and Manchester clinical criteria [1]. Nevertheless, the above mentioned criteria may
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have high sensitivity but lack specificity since FTD and AD patients may be similarly impaired
in several cognitive tasks [6] and in many cases the definite diagnosis of the dementia subtype is
based on the postmortem examination of the brain [7].
Although clinical examination and specific cognitive tests have been used in discriminating
these disorders, there are frequently difficulties in clinical practice due to the overlapping of sev-
eral features.
Brain perfusion studies with single photon emission computed tomography (SPECT) have
been applied in demented patients in order to provide better discrimination between FTD and AD
patients [8–10]. SPECT studies have been evaluated either by visual interpretation or using semi-
quantitative analysis. Several processing protocols for 3D voxel-by-voxel analysis of brain perfu-
sion SPECT have been applied, mainly the three-dimensional stereotactic surface projection (3D-
SSP) [11] and the statistical parametric mapping (SPM) [12] and recently the NeuroGam software.
Although many studies have been published dealing with brain perfusion abnormalities in AD
and FTD, which have validated the characteristic patterns of cortex perfusion in the above demented
disorders [13–15], there is negligible literature concerning the perfusion in strictly defined cortical
functional areas, i.e. the Brodmann (Br) areas.
The aim of our study was to evaluate the perfusion of specific Br areas of the brain cortex in
FTD and AD patients, using NeuroGam processing program.
2 Materials and methods
2.1 Population
Thirty four consecutive patients from the outpatient Memory Clinic of the General Hospital “G,
Gennimatas” were included in this study. We used the established DSM-IV criteria for the diag-
nosis of dementia and a neuropsychological evaluation with a battery of tests including the mini-
mental state examination (MMSE). All the patients had either a computed tomography (CT) or
a magnetic resonance imaging (MRI) of the brain in order to exclude the presence of vascular or
structural brain lesions. Twenty six patients received the clinical diagnosis of FTD: 16 males and 10
females, age 68.76±6.51 years, MMSE 16.69±9.89, education 11.81±4.25 years. Eight patients
received the clinical diagnosis of AD: all females, age 71.25±10.48 years, MMSE 12.5±3.89,
education 10±4.6 years.
Pregnant women, patients with a history of psychiatric disorders and patients with a history,
signs or findings of other neurological disorders were excluded.
Before testing, all patients gave informed consent for their participation, according to the
Hospital Ethics Committee guidelines (based on the ethical guidelines of the 1975 Declaration
of Helsinki).
Prior to the study, patients were also given written directions on radioprotection.
2.2 SPECT studies
All the patients underwent a brain SPECT scan after the intravenous administration of 740MBq
of 99mTechnetium hexamethyl propylene amine oxime (HMPAO) (Ceretec, Amersham) in a quite
room with the eyes open.
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SPECT studies were performed 20 min after the administration of the radiopharmaceutical
using a tomographic camera (Sophy NxT) equipped with a low-energy ultra high resolution parallel
hole collimator. Images were acquired in step-and-shoot mode (128 projections, 35 sec/projection)
on a 128x128 matrix and the photopeak was centered at 140 keV with a symmetrical 10% window.
Images were reconstructed using the filtered back projection technique. Smoothing was performed
with a Generic Weiner filter. No attenuation correction has been applied.
2.3 NeuroGam protocol
We applied the NeuroGamTM (Segami-Corporation, www.segamicorp.com) software on the re-
constructed data, for the evaluation of brain perfusion in specific Br areas in the left and right
hemispheres. NeuroGam is a comprehensive package for the display and quantification of func-
tional brain studies, allowing differential analysis of activation studies by using an automatic reg-
istration algorithm. This software applies an affine co-registration by blocks of data defined in the
Talairach space. Each hemisphere is subdivided in six rectangular volumes which undergo a spe-
cific affine transformation to fit the Talairach atlas. There is no additional smoothing performed.
The method allows for quantitative and qualitative comparison of sequential brain images on the
same patient as well as brain images on a given patient either with a normal database or with dis-
ease specific database, creation of normal and disease specific database and — the most interesting
— the quantitative analysis of brain images according to predefined Br functional areas.
Count normalization was performed using cerebellum as the reference area, which is consid-
ered to be the least affected area in degenerative dementias.
2.4 Statistical analysis
Continuous data are expressed as mean± standard deviation. The normality assumption of contin-
uous variables was evaluated using Kolmogorov-Smirnov criterion. In order to test differences of
the rCBF in Br areas between the AD and FTD groups, the unpaired Student t-tests were used.
All p values reported are two-tailed. Statistical significance was set at 0.05. Analyses were
conducted using the STATA statistical software (version 6.0).
2.5 Results
A total of 34 patients (26 FTD and 8 AD) participated in the study. Age (p=0.421), years of
education (p=0.309), and MMSE score (p=0.254), did not differ significantly between FTD and
AD group of patients. Perfusion was significantly lower in AD compared to FTD patients in the
following Br areas: 7R and 39R (p<0.05) (figure 1). Additionally, significant hypoperfusion was
found in FTD patients compared to AD patients, in the following Br areas: 11L (p<0.0001), 11R,
20L, 20R, 32L, 38L, 38R, 44L (p<0.001), 32R, 36L, 36R, 45L, 45R, 47R (p<0.01), 9L, 21L, 44R,
46R, 47L (p<0.05) (figure 2).
3 Discussion
SPECT is widely available and offers a sensitive diagnostic tool for the assessment of rCBF in FTD
and AD patients demonstrating characteristic patterns of perfusion abnormalities in the aforemen-
tioned disorders. Bilateral hypoperfusion in the posterior temporoparietal regions with variable
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Figure 1. Brain perfusion SPECT of an Alzheimer’s disease patient, exhibiting bilateral hypoperfusion in
parietal lobes. (A) visual assessment and (B) quantitative analysis in Brodmann areas using NeuroGam
software.
frontal lobe involvement was considered characteristic for AD [13, 14], while hypoperfusion in
the frontal cortex and anterior parietal lobes was seen in FTD patients [14, 15]. Beyond to visual
interpretation, region of interest (ROI) analysis has been used for the semiquantitative evaluation
of brain SPECT studies. However, in some cases these patients may share common rCBF abnor-
malities and the visual analysis and/or the ROI approach may not sensitively detect more localised
focal changes that could be more specific for each pathology. For example, the reported incidence
of the typical perfusion pattern in the more advanced stages of AD varies from 30% to 100% [16].
The use of methods that achieve statistical manipulation of SPECT images after anatomical
standardization, such as three-dimensional stereotactic surface projection (3D-SSP) [11, 17] and
statistical parametric mapping (SPM) [12], and recently NeuroGam software, may eliminate inter-
observer variations and detect subtle decreases in brain perfusion, indistinguishable by human eyes.
According to our results, the Br areas which demonstrated hypoperfusion in FTD patients
compared to AD patients are located in the frontal (Br areas 9L, 11L, 11R, 32L, 32R, 44L, 44R,
45L, 45R, 46R, 47L, 47R) and temporal (Br areas 20L, 20R, 21L, 36L, 36R, 38L, 38R) lobes.
Similarly, the Br areas which found to be hypoperfused in AD patients compared to FTD patients
are located in the parietal lobe. Our results are in general concordance with the published findings
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Figure 2. Brain perfusion SPECT of a patient with Frontotemporal dementia, showing hypoperfusion in
frontal lobes, mainly on the right. (A) visual assessment and (B) quantitative analysis in Brodmann areas
using NeuroGam software.
of several previous studies [8, 18, 19]. These groups demonstrated characteristic perfusion patterns
in each disorder and therefore confirm the preferential involvement of the frontotemporal regions
in FTD patients and of the parietal regions in AD patients.
To our knowledge, this is the first study comparing rCBF in specific Br areas between AD and
FTD patients. Brain perfusion mapping using NeuroGam processing protocol results in enhanced
detection of small differences in rCBF between FTD and AD patients. The use of this processing
method could highlight the networks that are more specifically impaired in these disorders and
might be involved in the emotional-behavioural and cognitive disturbances that characterise FTD
and AD respectively. In addition, this approach reduces the operator’s subjectivity and the time
required for data analysis. Furthermore, NeuroGam can be used for reliable inter-subject compar-
isons because the data is transformed into a standard atlas.
3.1 Conclusion
In conclusion, our results suggest that the application of NeuroGam processing protocol offers
a more detailed and objective evaluation of rCBF and may contribute to a better discrimination
between FTD and AD patients. The results of the present study were derived from a small cohort of
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patients, and need to be replicated in a larger sample population. Moreover the comparison between
perfusion in Br areas with clinical and neuropsychological parameters in demented patients, needs
further investigation.
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